Innovus Pharmaceuticals (OTCMKTS:INNV) Upgraded at Zacks Investment Research

Share on StockTwits

Zacks Investment Research upgraded shares of Innovus Pharmaceuticals (OTCMKTS:INNV) from a sell rating to a hold rating in a report published on Thursday, June 7th.

According to Zacks, “Innovus Pharmaceuticals, Inc. is a commercial-stage pharmaceutical company. It delivers non-prescription medicine and consumer care products to improve men’s and women’s health and vitality. It has a robust portfolio of sexual dysfunction treatments, cough, cold, respiratory disease treatments and pain management medication, as well as skin care products. Its male and female sexual health and vitality products include Zestra (R) to increase desire, arousal, and satisfaction in women; EjectDelay (R) for treating premature ejaculation; Sensum+ (TM) that increases penile sensitivity; Zestra Glide (R); and Vesele (R) to maximize nitric oxide beneficial effects on sexual functions and brain health. Innovus Pharmaceuticals, Inc. is based in San Diego, California. “

Separately, ValuEngine raised Innovus Pharmaceuticals from a sell rating to a hold rating in a report on Wednesday, May 2nd.

OTCMKTS:INNV opened at $0.11 on Thursday. Innovus Pharmaceuticals has a 52-week low of $0.08 and a 52-week high of $0.21.

Innovus Pharmaceuticals (OTCMKTS:INNV) last released its quarterly earnings results on Monday, April 2nd. The company reported ($0.01) earnings per share (EPS) for the quarter. Innovus Pharmaceuticals had a negative net margin of 51.76% and a negative return on equity of 273.00%. The company had revenue of $2.38 million for the quarter. equities analysts predict that Innovus Pharmaceuticals will post -0.01 earnings per share for the current fiscal year.

About Innovus Pharmaceuticals

Innovus Pharmaceuticals, Inc, a pharmaceutical company, engages in the commercialization, licensing, and development of non-prescription medicine and consumer care products in the United States. Its products include Zestra, a proprietary blend of essential oils to enhance desire, arousal, and satisfaction in women; EjectDelay, an over-the-counter monograph-compliant benzocaine gel for premature ejaculation; Sensum+, a non-medicated cream that enhances penile sensitivity; Zestra Glide, a water-based longer lasting lubricant; Vesele, a proprietary oral supplement of Arginine sexual and cognitive functions; and Androferti, a natural supplement to support overall male reproductive health and sperm quality.

Get a free copy of the Zacks research report on Innovus Pharmaceuticals (INNV)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Innovus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innovus Pharmaceuticals and related companies with's FREE daily email newsletter.

Leave a Reply